a single arm open label international multi center study of the efficacy and safety of sunitinib malate (su011248, sutent�) in patients with progressive advanced metastatic well differentiated unresectable pancreatic neuroendocrine tumors.
Read time: 1 mins
Last updated:24th Jan 2012
To confirm sunitinib treatment effect on progression-free survival (PFS) per investigator assessment in subjects with advanced/metastatic, well differentiated, unresectable, pancreatic neuroendocrine tumors per RECIST.
|Study start date||2012-01-24|